Kura Oncology to Report Second Quarter 2021 Financial Results

Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company, will announce its second quarter 2021 financial results on August 5, 2021, after market close. A webcast and conference call will follow at 4:30 p.m. ET. The company is focused on precision medicines for cancer treatment, with several drug candidates including KO-539 for acute myeloid leukemia and tipifarnib for HRAS mutant head and neck squamous cell carcinoma. Kura's therapies aim to target specific cancer pathways and improve patient outcomes.

Positive

• Kura's pipeline includes KO-539 in a Phase 1/2 trial targeting relapsed/refractory acute myeloid leukemia.
• Tipifarnib has received Breakthrough Therapy Designation for HRAS mutant head and neck squamous cell carcinoma.

Negative

• None.

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 516-3514 for domestic callers and (281) 973-6129 for international callers and entering the conference code: 3171857. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets, including patients who have HRAS and/or PIK3CA-dependent HNSCC. The Company is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

What are Kura Oncology's financial results report dates for Q2 2021?

Kura Oncology will report its second quarter 2021 financial results on August 5, 2021.

What is the significance of the KO-539 drug for Kura Oncology?

KO-539 is in a Phase 1/2 trial targeting patients with relapsed/refractory acute myeloid leukemia.

What is the Breakthrough Therapy Designation received by Kura Oncology?

Tipifarnib received Breakthrough Therapy Designation for treating HRAS mutant head and neck squamous cell carcinoma.